Expectations trend
FY2027 · fiscal year ending 2027-12-27 · fmp
Charles River Laboratories (CRL)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
$313.02-4.07%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
12.78 → 12.80 EPS · FY ending Dec 27, 2027 · 10 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 10 to 10; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for CRL yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
EPS near $11.3 or better | The company expects EPS near $11.3 in 2026 and repurchased $200 million of stock in Q1. | Intact | EPS falls below $10.8 in FY26 | Diluted EPS: $6.86 per share FY2026-Q3; GAAP. Published target: >= $10.8 per share. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 20266.86 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-27 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
CRL is a research-services business with a multi-year view tied to continued financial execution and client demand. The thesis is intact after recent earnings beats and a guidance increase, though management’s portfolio changes and client-focused efforts have had mixed broad revenue results so far.
Valuation is expensive versus peers, and the expectations gap is positive, indicating that expectations are somewhat ahead of the model’s baseline. The stretched tag points to demanding assumptions, although no evidence indicates unusually fragile pricing.
Recent financial performance is strong, with two reported earnings beats and guidance raised in August. Near term, revenue was down year over year in the second quarter, partly due to divestitures, while overall organic revenue was flat to slightly negative. The miss risk is described as low, but weakening earnings surprises and a history of a deep miss remain risks.
A key risk is whether CRL can sustain its raised guidance; reversing course could damage management credibility. Weaker job growth could increase recession concerns for cyclical businesses, while continued strong results and higher guidance from healthcare peers could support sector momentum. The impact of portfolio changes and client-focused initiatives on broad revenue growth also remains important.
For the next 1 to 3 years, the thesis remains intact, but expensive valuation raises the stakes for continued execution and revenue improvement. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Charles River Laboratories's published investment case. The stated target is >= -1.5% YoY. |
| Intact |
| YoY revenue growth falls below -1.5% in FY26 |
Revenue growth: -2.2% FY2026-Q3; GAAP. Published target: >= -1.5% YoY. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 2026-2.201319 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Continue stock repurchases of at least $200 million in Q1 | The company expects EPS near $11.3 in 2026 and repurchased $200 million of stock in Q1. | Intact | Stock repurchases fall significantly below $200 million in Q1 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$12.35 → $12.80 · observed estimates
$3.92B → $4.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $12.35 | $3,918,241,773 | 10 / 12 |
| 2026-07-25 | $12.35 | $3,918,241,773 | 10 / 12 |
| 2026-07-26 | $12.35 | $3,918,241,773 | 10 / 12 |
| 2026-07-27 | $12.35 | $3,918,241,773 | 10 / 12 |
| 2026-07-28 | $12.35 | $3,918,241,773 | 10 / 12 |
| 2026-07-29 | $12.35 | $3,918,241,773 | 10 / 12 |
| 2026-07-30 | $12.35 | $3,918,241,773 | 10 / 12 |
| 2026-07-31 | $12.35 | $3,918,241,773 | 10 / 11 |
| 2026-08-01 | $12.35 | $3,918,241,773 | 10 / 11 |
| 2026-08-02 | $12.35 | $3,918,241,773 | 10 / 11 |
| 2026-08-03 | $12.35 | $3,918,241,773 | 10 / 11 |
| 2026-08-04 | $12.35 | $3,918,241,773 | 10 / 11 |
| 2026-08-05 | $12.35 | $3,918,241,773 | 10 / 11 |
| 2026-08-06 | $12.35 | $3,918,241,773 | 10 / 11 |
| 2026-08-07 | $12.55 | $3,943,826,674 | 9 / 11 |
| 2026-08-08 | $12.55 | $3,943,826,674 | 9 / 11 |
| 2026-08-09 | $12.55 | $3,943,826,674 | 9 / 11 |
| 2026-08-10 | $12.55 | $3,943,826,674 | 9 / 11 |
| 2026-08-11 | $12.55 | $3,943,826,674 | 9 / 11 |
| 2026-08-12 | $12.55 | $3,943,826,674 | 9 / 11 |
| 2026-08-13 | $12.55 | $3,943,826,674 | 9 / 11 |
| 2026-08-14 | $12.55 | $3,943,826,674 | 9 / 11 |
| 2026-08-15 | $12.55 | $3,943,826,674 | 10 / 11 |
| 2026-08-16 | $12.55 | $3,943,826,674 | 10 / 11 |
| 2026-08-17 | $12.55 | $3,943,826,674 | 10 / 11 |
| 2026-08-18 | $12.55 | $3,943,826,674 | 10 / 11 |
| 2026-08-19 | $12.55 | $3,943,826,674 | 10 / 11 |
| 2026-08-20 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-08-21 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-08-22 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-08-23 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-08-24 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-08-25 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-08-26 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-08-27 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-08-28 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-08-29 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-08-30 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-08-31 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-09-01 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-09-02 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-09-03 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-09-04 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-09-05 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-09-06 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-09-07 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-09-08 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-09-09 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-09-10 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-09-11 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-09-12 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-09-13 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-09-14 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-09-15 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-09-16 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-09-17 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-09-18 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-09-19 | $12.73 | $3,986,576,968 | 10 / 11 |
| 2026-09-20 | $12.76 | $3,986,576,968 | 10 / 11 |
| 2026-09-21 | $12.76 | $3,986,579,367 | 10 / 11 |
| 2026-09-22 | $12.75 | $3,987,347,984 | 11 / 11 |
| 2026-09-23 | $12.76 | $3,987,347,984 | 11 / 11 |
| 2026-09-24 | $12.76 | $3,987,347,984 | 11 / 11 |
| 2026-09-25 | $12.77 | $3,989,492,269 | 10 / 11 |
| 2026-09-26 | $12.76 | $3,988,410,681 | 10 / 11 |
| 2026-09-27 | $12.76 | $3,988,410,681 | 10 / 11 |
| 2026-09-28 | $12.74 | $3,991,024,346 | 10 / 11 |
| 2026-09-29 | $12.74 | $3,991,024,382 | 10 / 11 |
| 2026-09-30 | $12.74 | $3,991,024,382 | 10 / 11 |
| 2026-10-01 | $12.78 | $3,993,533,030 | 10 / 12 |
| 2026-10-02 | $12.78 | $3,993,533,030 | 10 / 12 |
| 2026-10-03 | $12.78 | $3,993,533,030 | 10 / 12 |
| 2026-10-04 | $12.78 | $3,993,533,030 | 10 / 12 |
| 2026-10-05 | $12.78 | $3,993,533,030 | 10 / 12 |
| 2026-10-06 | $12.78 | $4,002,733,030 | 10 / 12 |
| 2026-10-07 | $12.78 | $4,002,746,363 | 10 / 12 |
| 2026-10-08 | $12.82 | $4,010,618,682 | 10 / 12 |
| 2026-10-09 | $12.82 | $4,010,613,030 | 10 / 12 |
| 2026-10-10 | $12.82 | $4,010,613,030 | 10 / 12 |
| 2026-10-11 | $12.82 | $4,010,613,030 | 10 / 12 |
| 2026-10-12 | $12.82 | $4,010,613,030 | 10 / 12 |
| 2026-10-13 | $12.82 | $4,010,613,030 | 10 / 12 |
| 2026-10-14 | $12.82 | $4,013,437,446 | 10 / 12 |
| 2026-10-15 | $12.82 | $4,013,437,446 | 10 / 12 |
| 2026-10-16 | $12.80 | $4,011,372,186 | 10 / 12 |
| 2026-10-17 | $12.80 | $4,011,372,186 | 10 / 12 |
| 2026-10-18 | $12.80 | $4,012,112,186 | 10 / 12 |
| 2026-10-19 | $12.80 | $4,012,112,186 | 10 / 12 |
| 2026-10-20 | $12.80 | $4,012,112,186 | 10 / 12 |
| 2026-10-21 | $12.80 | $4,012,112,186 | 10 / 12 |
| 2026-10-22 | $12.80 | $4,012,290,209 | 10 / 12 |
| 2026-10-23 | $12.80 | $4,012,290,209 | 10 / 12 |
| 2026-10-24 | $12.80 | $4,012,097,352 | 10 / 12 |
| 2026-10-25 | $12.80 | $4,012,097,352 | 10 / 12 |
| 2026-10-26 | $12.80 | $4,012,097,352 | 10 / 12 |
| 2026-10-27 | $12.80 | $4,012,097,352 | 10 / 12 |
| 2026-10-28 | $12.80 | $4,012,097,352 | 10 / 12 |
| 2026-10-29 | $12.80 | $4,012,097,352 | 10 / 12 |
| 2026-10-30 | $12.80 | $4,012,097,352 | 10 / 12 |
| 2026-10-31 | $12.80 | $4,012,097,352 | 10 / 12 |
| 2026-11-01 | $12.80 | $4,012,097,352 | 10 / 12 |
| 2026-11-02 | $12.80 | $4,012,097,352 | 10 / 12 |
| 2026-11-03 | $12.80 | $4,012,097,352 | 10 / 12 |
| 2026-11-04 | $12.80 | $4,012,097,352 | 10 / 12 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 14 Buy / Strong Buy · 2 Hold · 1 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.